The diversity of infectious agents capable of inducing meningitis and blood-brain barrier (BBB) injury suggests the potential for a common host mediator. The inflammatory polypeptides, IL-1 and TNF, were tested in an experimental rat model as candidate mediators for induction of meningitis and BBB injury. Intracisternal challenge ofrII-l-into rats induced neutrophil emigration into cerebrospinal fluid (CSF) and significantly increased BBB permeability to systemically administered 12511 BSA as early as 3 h later (P < 0.05). This injury was reversible, dose dependent and significantly inhibited by prior induction of systemic neutropenia (via intraperitoneal cyclophosphamide) or preincubation of the rIL-1,6 inoculum (50 U) with an IgG monoclonal antibody to rIL-1#,. Similar kinetics and reversibility of CSF inflammation and BSA permeability were observed using equivalent dose inocula of rIL-1 alpha. rTNF-a was less effective as an independent inducer of meningitis or BBB injury over an inoculum range of 10' U (0.0016 ,ug/kg)-10' U (160 ag/kg) when injected intracisternally, but inoculum combinations of low concentrations of rTNFa (103 U) and rIL-1l (0.0005-5.0 U) were synergistic in inducing both meningitis and BBB permeability to systemic 125I-BSA. These data suggest that in situ generation of interleukin-1 within CSF (with or without TNF) is capable of mediating both meningeal inflammation and BBB injury seen in various central nervous system infections. (J. Clin.
Introduction
Bacterial meningitis remains a substantial health problem accounting for worldwide morbidity and mortality. As such, it represents a unique dichotomy in human infectious disease since available antimicrobial agents achieve bactericidal concentrations within the central nervous system (CNS)' capable of microbiologic cure. This observation supports the hypothesis that the pathophysiologic sequelae ofthe disease beyond the leptomeninges, but within the CNS, progress despite bacterial eradication and effect permanent neuronal injury (1) .
The blood-brain barrier (BBB), ultrastructurally localized at the cerebral microvascular endothelium (2) , represents a vital extrameningeal focus of injury in meningitis. Indeed, BBB injury, with its associated alteration in albumin transcytosis represents the major precipitant of vasogenic brain edema observed in many forms ofCNS infections in humans and experimental animals. Previous investigations in an experimental rat model of meningitis have demonstrated consistent ultrastructural and functional alterations of the BBB after intracisternal challenge with live bacteria as well as bacterial cell surface constituents (3, 4) . This observation of diverse challenge inocula eliciting a uniform host injury suggests that one or more endogenous inflammatory mediators might be involved.
The polypeptide IL-l, an inflammatory cytokine and immunomodulator, represents such a candidate mediator ofmeningitis and BBB injury given its stimulation by various infectious agents, its ability to enhance neutrophil adherence to endothelium in vitro (5) , and the presence of its gene within resident cells of the central nervous system.
The goals ofthis inquiry were to ask: (a) does intracisternal challenge with IL-l generate an inflammatory response in the cerebrospinal fluid; (b) is there a time/dose-dependent injury to the BBB similar to that observed in challenge with live bacteria or bacterial surface components; (c) is the BBB injury observed dependent upon neutrophil exudation into CSF; (d) does intracisternal challenge with TNF, an inflammatory cytokine with similar in vivo and in vitro effects as IL-1, elicit a similar injury pattern; and (e) is there a synergistic effect observed upon intracisternal challenge of IL-l with TNF?
Methods
Challenge inocula. Recombinant human IL-10 (isoelectric point [pI 7 .0]) and IL-la (pI 5.0), the translation products ofthe cloned complementary DNA isolated from a macrophage cDNA library, were purchased from Cistron (Pine Brook, NJ). They were diluted in PBS with 2 ,uM dithiothreitol (DTT) (Bio-Rad Laboratories, Richmond, CA) and 0.1% BSA. Each contained 1,000 U/ml of thymocyte costimulation activity (1 ng Plains, NJ) and xylazine (Miles Laboratories, Shawnee, KS) intramuscularly at a dose of 100 mg/kg and 8 mg/kg, respectively. After removal of CSF using a 25-gauge butterfly needle (Abbott Inc., North Chicago, IL), 50 10 ofthe challenge inoculum was injected into each experimental group and 0.1% BSA with 2 MM DTT inoculated into simultaneous matched controls. 1 h before the second cisternal puncture, rats had intracardiac administration of 10 MCi '25I-BSA (ICN Radiochemicals, Irvine, CA). At the time ofthe second cisternal puncture, simultaneous CSF and blood samples were obtained for assay of 1251 cpm in a Gamma 300 counter (Beckman Instruments, Inc., Irvine, CA) as well as CSF leukocyte concentration using a hemocytometer. Only CSF samples without visible blood contamination were evaluated. The percentage ofCSF penetration of '25I-BSA was determined from the equation: cpm per ml CSF/cpm per ml blood X 100.
Experimental groups consisted of: group I, inoculated with rIL-Ij; group II, inoculated with rIL-la; group III, inoculated with rIL-lIl preincubated (12 h at 40C) with mouse IgG monoclonal Ab (1:50 dilution) to rIL-lIB; group IV, inoculated with rIL-lI preincubated with polymyxin B (2 Ag/ml); group V, inoculated with rIL-1,6 four days after induction of leukopenia with 100 mg/kg cyclophosphamide (Adria Laboratories, Columbus, OH) intraperitoneally (only animals with blood WBC < 1,000/mm3 were used); group VI, inoculated with rTNFa; group VII, inoculated with rIL-l#j combined with rTNFa. (mean±SE '251-BSA penetration, 4.23±0.73%), compared to controls (mean±SE '25I-BSA penetration, 0.94±0.42%; P < 0.05), that was reversible by 6 h and remained so for the 24-h observation period. This effect was in contrast with 10' U rTNFa as the intracisternal inoculum which elicited no significant 1251-BSA CSF penetration for as long as 24 h later (mean±SE '25I-BSA penetration, 0.73±0.25%), an observation that paralleled the minimal CSF inflammation it provoked.
(b) Dose dependence. As noted for leukocyte exudation, when the CSF was sampled 3.5 h after intracisternal inoculation with rIL-l #, the effect on BBBP to '25I-BSA was dose dependent. The mean (+SE) 1251I-BSA penetration into CSF was maximal (4.29±0.83%) compared with controls (0.60±0.15%; P < 0.005) with a 25-U (0.2 ,g/kg) inoculum, but was significantly increased (P < 0.05) with as low as a 5-U inoculum (2.07±0.51%). Conversely, intracisternal inoculation with rTNFa doses ranging from 10' U (0.02 ,ug/kg) to 106 U (160 ag/kg) elicited no significant change in BSA penetration into CSF (mean+SE 125I-BSA CSF penetration = 0.64±0.17% using a 103-U inoculum) (see Fig. 4 ).
3. rIL-JIc vs. rIL-1If induction of CSF pleocytosis and BBB permeability
To assess whether IL-I a (pI 5.0) (which shares many biological properties and recognizes the same receptor as IL-13) could induce a similar in vivo response, the time course of CSF inflammation and BBB injury was determined using 50 U of IL-a as an intracisternal inoculum. As shown in Table I , intracisternal inoculation of rIL-lIa induced very similar kinetics of CSF inflammation (mean±SE WBC = 11.3±2.6 X 103/mm3) and CSF 125I-BSA penetration (mean+SE '25I-BSA = 2.8±0.8%) that were reversible 4 h later, analogous to that seen with rIL-1#. 4 . rIL-I1f-induced CSF pleocytosis and BBB injury: influence ofleukopenia, polymyxin B and monoclonal antibody to rIL-I1
As noted in Table II, ternal inoculation of 50 U of rIL-1I# significantly reduced both CSF leukocyte exudation and BBB permeability to '251-BSA previously described in nonleukopenic animals (P < 0.001). In addition, Table II describes the influence of preincubation of the rIL-1I3 inoculum (50 U) with either polymyxin B (2 ,gg/ml) (5, (11) (12) (13) . Hence, in situ synthesis ofIL-I within the CSF as a consequence ofmeningeal infection could serve as a tropic factor localizing neutrophil adherence and emigration through the cerebral microvasculature with subsequent BBB injury.
As the initial investigation into this concept, we sought to characterize the potential ofintracisternal IL-I as an inducer of meningitis and BBB injury using a well characterized rat model. Recombinant human IL-1# (pI 7.0) was used to facili- tate purity of preparation and was selected as the major test inoculum because IL-(3 is the predominant extracellular form of IL-I in vivo (10, (14) (15) (16) . As shown in Figs. 1 and 2 , intracisternal inoculation of human rIL-13 induced both a time-and dose-dependent meningitis by emigration ofleukocytes (>95% neutrophils) into CSF. Significant CSF pleocytosis began 3 h postinoculation, peaked at 6 h, and was reversible by 24 h. Significant BBB injury, as measured by CSF traversal ofsystemically administered '25I-BSA, was concomitantly observed 3 h postinoculation, peaked between 3-4 h, and was reversible by 6 h. Both of these effects were dose dependent and were significant compared with controls with an inoculum as low as 5 U (5 ng) of rIL-1(3. The reversibility of BBB injury is intriguing and suggests either rapid clearance of rIL-1(3, generation of a soluble adhesion inhibitor (17) , or tachyphylaxis to its effect on the microvasculature similar to that described in other systems (18) . This dose-response effect of human rIL-1(3 in the rat model is similar to that recently reported by Ramilo et al. using 5-200 ng ofrecombinant rabbit IL-1(3 to induce experimental meningitis in rabbits (19) . Interestingly, recent preliminary data from our laboratory have documented that during H. influenzae Iipooligosaccharide-induced experimental meningitis, IL-I activity can be detected in CSF in a similar nanogram range. Specifically, after 20 ng of H. influenzae lipooligosaccharide intracisternal inoculation, up to 4.5 ng/ml of CSF IL-I activity can be detected 30 min later (20) . This is corroborated in recent human studies where IL-1(3 concentrations in the nanogram range were detectable in the CSF of children with bacterial meningitis (21) . However, precise correlation between detectable CSF concentrations of IL-1( during natural disease and the concentration necessary to induce experimental meningitis may be unrealistic for several reasons. First, there may be some species-specific ligand receptor interaction mandating a higher concentration ofhuman rIL-1(3 inoculum to induce experimental rat meningitis and BBB injury. Second, the IL-1(3 within the human CSF documented at clinical presentation has been present for hours or days and is likely continuously synthesized and secreted as long as bacteria (and their surface components) are present. This contrasts with the experimental models in which the rIL-1(3 inoculum is given as a single pulse dose, an experimental design in which a higher rIL-1( inoculum concentration may be necessary to induce disease. Third, the IL-1(3 measured within CSF during natural disease is likely acting in concert with other inflammatory peptides (e.g., TNF, macrophage inflammatory protein (MIP), GM-CSF) to induce the observed meningeal inflammation. Thus, one can expect that a higher concentration of IL-1(3 would be necessary to induce meningitis when given exogenously as the sole stimulus.
As noted previously, IL-1(3 is the predominant form ofIL-1 as observed in vitro and in vivo. The amount of IL-1(3 mRNA in activated cells is up to 50-fold greater than IL-la and culture supernatents of human body fluids contain more IL-l( than IL-ia (16) . Nonetheless, despite different amino acid sequences, IL-la and IL-1(3 are structurally related by crystallographic analysis and recognize the same receptor. Hence, parallel experiments were done using rIL-1 a as an intracisternal inoculum and its time course of inducible CSF inflammation and BBB injury were compared with rIL-1(3. As shown in Table  I , 50 U of rIL-1 a inoculated intracisternally induced a CSF pleocytosis and "25I-BSA permeability similar to rIL-l(I. However, the IL-i a response was slower in onset, its induced CSF inflammation less intense, and its induced BBB permeability more transient than that seen with IL-1(. These observations parallel other experimental observations showing that both forms of IL-1 are capable of inducing systemic acute phase responses, sleep, as well as augmentation of B, T, and natural killer cell responses (16) . To elucidate whether the injury to the cerebral microvasculature allowing for '25I-BSA penetration was an effect of the inflammatory neutrophil response or an independent effect of IL-I on the endothelium, experiments were repeated in leukopenic animals. As shown in Table II , when rats rendered systemically leukopenic were inoculated with 50 U of rIL-I( into a CSF pleocytosis was prevented and BBB injury was not observed. This observation is similar to recent findings in the same model using H. influenzae lipooligosaccharide as an inoculum (4), and supports the hypothesis that the BBB injury due to a pulse inoculum, of IL-I is neutrophil dependent. Limitations of this model prevent observations of the effect of a sustained IL-I inoculum in CSF over several hours (i.e., by continuous infusion); such experiments are worth pursuing since IL-I may effect an independent injury to endothelium with a more prolonged exposure. Nonetheless, the precise mechanism in which IL-1 and emigrating neutrophils interact to induce cerebral microvascular injury and '25I-BSA transcytosis is unknown but may be related to generation of additional neutrophil-activating peptides (e.g., c5a, GM-CSF) within the CSF (22) . Although endotoxin activity was virtually undetectable in the rIL-1(3 preparation, control experiments were done to ensure that the biological effect was indeed due to the cytokine.
As shown in Table II , preincubation of the rIL-1( inoculum (50 U) with polymyxin B did not significantly alter either CSF emigration of neutrophils or BBB permeability to 1251I-BSA.
However, preincubation with a mouse monoclonal IgG antibody to human rIL-1(3 significantly reduced both CSF pleocytosis as well as BBB permeability to '25I-BSA; an effect not seen with a control monoclonal antibody. These observations reinforce that it was indeed the rIL-1( in the test inoculum that was inducing the observed meningitis and BBB injury.
TNFa, a cytokine produced by the monocyte/macrophage in response to lipopolysaccharide (23) , induces similar biologic effects ascribed to IL-I including pyrogenicity (24) , alteration of endothelial hemostasis (25, 26) , and induction of leukocyteendothelial cell adhesion in vitro (27) . Since it thus represented an additional potential mediator of meningitis and BBB injury, we compared the effect of intracisternal challenge with human rTNFa to the effect of rIL-1(. As demonstrated in Fig. 1-4 To assess directly whether the combination of TNF and IL-1 might exhibit a synergistic inflammatory effect, the final experiment combined rTNFa and rIL-1I3 as an intracisternal inoculum. As shown in Table III , although an rTNFa inoculum of IO' U was without independent effect, the addition of rIL-1( as low as 0.05 U to the rTNFa induced a synergistic effect in both CSF neutrophil emigration and BBB permeability to systemic 2'21-BSA. The synergism of these cytokines in this response is similar to that observed in other experimental systems including the induction of shock (32) , the Shwartzman reaction (33) , as well as muscle catabolism in the rat (34 In total, these experimental observations strongly support a critical biological role of these cytokines, in the induction of CSF inflammation and BBB injury and suggest their potential as specific targets for therapeutic intervention in humans.
